Business Context and Reporting Period
Company: Fitness Champs Holdings Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2026 (Specifically covering events from April 17 to April 22, 2026)
Event: Pricing and closing of a best efforts public offering of units.
Key Financial Metrics
The filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Approximately $5,000,000.
- Units Sold: 3,225,000 Units.
- Offering Price: $1.55 per Unit.
- Placement Agent Fees: 5% of gross proceeds (cash fee) plus 1% non-accountable expenses allowance.
- Other Expenses: Reimbursement for legal and out-of-pocket fees up to $100,000.
- Warrant Exercise Price: $2.635 per share.
- Warrant Expiration: Six months from issuance date.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new equity and warrants. The offering closed on April 20, 2026, following pricing on April 17, 2026. The transaction increases the number of outstanding Class A ordinary shares and introduces new warrant obligations.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds for research and development, business expansion, general working capital, and other general corporate purposes.
Lock-Up Agreements: The Company, its directors, executive officers, and beneficial owners of 5% or more of outstanding shares are subject to a 90-day lock-up agreement from the closing date, restricting the sale or disposal of shares without the Placement Agent's consent.
Beneficial Ownership Limits: Pre-Funded Warrants are subject to beneficial ownership limitations (4.99% or up to 9.99% at the holder's election) to prevent excessive concentration of ownership upon exercise.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 5% placement fee, 1% expense allowance, and legal costs.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Review the full text of the Securities Purchase Agreement and Placement Agency Agreement (Exhibits 10.1 and 10.2) for specific covenants.
- Monitor the exercise of Pre-Funded Warrants and the potential issuance of up to 48,375,000 shares under the "zero exercise price option."
- Check for any subsequent filings regarding the actual deployment of funds for R&D and expansion.